Biosimilar Law Experts Discuss Potential Bills and Chances for Passage

Despite the United States having had a biosimilar pathway for a decade now, the industry has launched just 17 biosimilars on the market, well behind the pace in Europe and India. Several pieces of legislation have been introduced in Congress to help boost uptake, generate savings for payers and patients, and increase biosimilar access. However, not every bill is likely to become a law, as politics and money can often get in the way.

We sat down with Ha Kung Wong, an intellectual property law attorney and partner at Venable Fitzpatrick in New York and April Breyer Menon, an expert on biosimilar patent law and founder of April Breyer Consulting in Chicago, Illinois, to discuss potential bills to improve biosimilar uptake and their chances for passage.

To learn more about Venable Fitzpatrick, visit venable.com.

To learn more about the Biologic Patent Transparency Act, visit congress.gov.

To learn more about the Affordable and Safe Prescription Drug Importation Act, visit congress.gov.

To learn more about the BIOSIM Act, visit congress.gov.